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Abstract
Background: Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling pathways. In patients with
advanced colorectal cancer and liver metastases, the effect of vandetanib on tumor vasculature was assessed using
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
Methods: Eligible patients received vandetanib 100 or 300 mg/day. DCE-MRI (iAUC60 and Ktrans) was used to quantify
the primary endpoints of tumor perfusion and vascular permeability. An exploratory assessment of tumor oxygenation
was performed using MRI/T2*. All MRI parameters were measured at baseline (twice) and on days 2, 8, 29 and 57.
Results: Twenty-two patients received vandetanib (n = 10, 100 mg; n = 12, 300 mg). Baseline measurements of iAUC60
and Ktrans were reproducible, with low intrapatient coefficients of variation (11% and 24%, respectively). Estimates of
mean % changes from baseline were -3.4% (100 mg) and -4.6% (300 mg) for iAUC60, and -4.6% (100 mg) and -2.7% (300
mg) for Ktrans; these changes were not significantly different between doses. The exploratory T2* measurement showed
a significant increase at 300 mg versus 100 mg (P = 0.006). Both doses of vandetanib were generally well tolerated;
common toxicities were fatigue, rash and diarrhea (majority CTC grade 1 or 2). The pharmacokinetic profile of
vandetanib was similar to that observed previously. There were no RECIST-defined objective responses; five patients
experienced stable disease ≥8 weeks.
Conclusion: In this study in patients with advanced colorectal cancer, vandetanib did not modulate gadolinium uptake
in tumor vasculature and tissue measured by the DCE-MRI parameters iAUC60 and Ktrans.
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Background
Vascular endothelial growth factor (VEGF) has a pivotal
role in tumor angiogenesis, which is required for the
growth of most solid tumors and the formation of metas-
tases. The VEGF signaling pathway is a validated therapeu-
tic target in several solid tumors, including advanced
colorectal cancer [1], non-small-cell lung cancer [2] and
renal cell carcinoma [3,4].
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) is a non-invasive functional imaging tech-
nique that permits indirect measurement of tumor hemo-
dynamics. It may therefore be suitable for monitoring the
effects of VEGF signaling inhibitors on tumor vasculature.
DCE-MRI utilizes a low molecular weight paramagnetic
contrast agent such as gadolinium-DTPA, which readily
diffuses from the blood to the extravascular extracellular
space. By acquiring a set of rapid MR images, the time
course of the change in T1 relaxation time induced by the
contrast agent may be followed. Contrast agent concentra-
tion can be calculated from T1 relaxation times using the
known linear relationship [5]. The time course obtained
can be characterized by the initial area under the contrast
agent concentration-time curve (iAUC) or a pharmacoki-
netic model may be applied. With the latter, the data are
fitted to estimate the transfer of contrast agent between
the plasma and the extracellular, extravascular space (the
transfer constant Ktrans). Although iAUC and Ktrans are
incompletely validated endpoints that are sensitive to
changes in a number of hemodynamic parameters,
including blood flow, blood volume, vessel permeability
and vessel surface area [6], emerging data from several
early-phase clinical trials of VEGF signaling inhibitors
have shown changes in Ktrans and/or iAUC that are consist-
ent with reductions in VEGF-dependent tumor perfusion
and vascular permeability [7-11].
Vandetanib (ZACTIMA™) is a once-daily oral anticancer
drug that selectively targets VEGFR-dependent tumor ang-
iogenesis and REarranged during Transfection (RET)- and
epidermal growth factor receptor (EGFR)-dependent
tumor cell proliferation and survival. Preclinical DCE-
MRI studies of vandetanib have demonstrated acute
effects on hemodynamic variables in human prostate and
colon xenograft models consistent with inhibition of
VEGF signaling [12,13]. Vandetanib is currently in phase
III development in advanced non-small-cell lung cancer
(NSCLC) and medullary thyroid cancer. Two doses of
vandetanib were selected for investigation in the present
study (100 mg and 300 mg). Previous phase I studies of
vandetanib have shown these doses to be well tolerated
and to achieve steady-state plasma levels that are likely to
be biologically active [14-16]. In addition, both doses
were clinically active as monotherapy in phase II studies
in NSCLC [17] and medullary thyroid cancer [18,19].
The primary objective of this open-label, randomized
phase I study (study code D4200C00050) was to assess by
DCE-MRI the effect of once-daily vandetanib on Ktrans and
iAUC60 (iAUC of the first 60 s after contrast agent arrival)
in patients with advanced colorectal cancer and liver
metastases. An exploratory objective was to investigate the
effects of vandetanib on the tumor by intrinsic susceptibil-
ity MRI, a technique that may have utility in measuring
tumor hypoxia in response to vascular disruption [20].
Methods
Patients
Eligible patients were adults with histologically confirmed
metastatic colorectal adenocarcinoma (stage IV) with at
least one measurable hepatic lesion ≥20 mm, WHO per-
formance status 0-2, life expectancy ≥12 weeks, and no
significant cardiac, hematopoietic, hepatic and renal dys-
function. Patients with brain metastases were eligible if
treated at least 4 weeks before the start of study treatment
and if clinically stable without steroid treatment for ≥10
days. Key exclusion criteria were previous chemotherapy
and/or radiotherapy (excluding palliative radiotherapy)
less than 4 weeks before the start of study therapy, a QTc
interval ≥480 ms during ECG screening, and poorly con-
trolled hypertension. Patients for whom MRI scanning is
contraindicated (e.g. pacemaker, heart valve replacement)
were also excluded.
Study design
In this open-label study, 24 patients were planned to be
randomized 1:1 to receive once-daily oral doses of vande-
tanib 100 mg or 300 mg. There was no stratification and
patients continued treatment until progressive disease,
withdrawal due to toxicity, patient lost to follow up,
severe non-compliance with the protocol or voluntary dis-
continuation by the patient. The primary objective of this
study was to assess by DCE-MRI the effect of once-daily
dosing with vandetanib on the tumor vasculature by
determining iAUC60  and Ktrans. Secondary assessments
included safety and tolerability, pharmacokinetics, and a
preliminary evaluation of efficacy. Exploratory assess-
ments included the effects of vandetanib on the tumor by
intrinsic susceptibility MRI, measurement of the target
tumor size by MRI, and the effect of vandetanib on solu-
ble markers of angiogenesis.
The trial was approved by the Bundesinstitut für Arzneim-
ittel und Medizinprodukte institutional review board/
research ethics committee, and was conducted in accord-
ance with the Declaration of Helsinki, Good Clinical Prac-Journal of Angiogenesis Research 2009, 1:5 http://www.jangiogenesis.com/content/1/1/5
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tice and the AstraZeneca policy on Bioethics. All patients
provided written informed consent.
Assessments
MRI
DCE-MRI and intrinsic susceptibility MRI (T2*) scans
were performed during the same scan session. To obtain
baseline and reproducibility measurements, two scans
were performed within 14 days before the start of vande-
tanib treatment (day 1) and the minimum time between
scans was 1 day. Subsequent scans were performed on
days 2, 8, 29 and 57. All DCE-MRI data were acquired
using a 1.5 T system (Magnetom Sonata, Siemens, Ger-
many). For the dynamic scan, a time series of inversion
recovery balanced SSFP (TrueFISP) images in one coronal
slice (d = 10 mm) cutting the liver target lesion were
acquired (α = 40°, TE = TR/2 = 1.24 ms). To obtain abso-
lute T1-relaxation rates at each time point of the time
series, images at seven inversion times after each inversion
pulse were used [21,22]. A dose of 0.1 mmol/kg Gd-DTPA
(Magnevist, Schering) was administered (3 mL/s) in a
peripheral vein using a contrast agent power injector
(Spectris, MEDRAD Inc.). To obtain a baseline measure-
ment without contrast agent, the measurement started 36
s before contrast agent administration. Altogether the
dynamic changes were determined for a period of 5 min
30 s with a temporal resolution of 3 s. The data obtained
were used to compute the change in contrast agent con-
centration over time. The concentration curve was then
fitted to obtain Ktrans  (the volume transfer constant
between blood plasma and extravascular, extracellular
space for contrast agent over the tumor region of interest
[ROI]) [23]. The iAUC60 was calculated over the tumor
ROI according to Evelhoch [24]. The ROIs were drawn
and semiautomatically tracked to all images of the time
series. The outline and tracking was checked by a second
person. The mean signal over the ROI was used as input
for the analysis. The longest diameter of the target lesion
evaluated by LDDCE-MRI was measured using anatomical
multi-slice transversal T1-w and T2-w MRI scans obtained
as part of the MRI acquisition protocol. The area of the tar-
get lesion evaluated by DCE-MRI was also measured as
part of the assessment. The reference lesions for the DCE-
MRI analysis were chosen by a radiologist at the screening.
The lesion had to be larger than 2 cm (longest diameter in
plane), clearly definable and not necrotic. Intrinsic sus-
ceptibility MRI consisted of a multi-gradient echo
sequence (TR = 65 ms; TE = 5.1-58.9 ms; 12 echoes)
acquired before contrast agent administration and was
used to determine T2* (effective transverse relaxation
time).
Efficacy
A preliminary assessment of efficacy was measured by
objective response rate and progression-free survival
(PFS) based on Response Evaluation Criteria in Solid
Tumors (RECIST). RECIST assessments were performed
by contrast-enhanced computed tomography (CT) at
baseline, day 57 and every 8 weeks thereafter. Subjects
who had not progressed or died at the time of analysis
were censored at the time of their latest assessment.
Safety and tolerability
Adverse events were reviewed at each scheduled visit and
graded according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 3. The possible relationship of an adverse event to
study treatment was assessed by the investigator. Twelve-
lead ECGs were performed during screening, pretreatment
(day 1), days 8, 15, 29, 57 and every 3 months thereafter.
Criteria for prolongation of the QTc interval were clearly
defined in the protocol. Patients who continued to receive
vandetanib beyond day 57 were anticipated to attend fol-
low-up visits every 4-6 weeks.
Blood sampling
To evaluate the pharmacokinetics in this patient popula-
tion, blood samples collected pre-dose on day 1, pre-dose
and 4-8 h post-dose on days 8, 15 and 29, and pre-dose
and at 4, 6, 8 and 24 hours post-dose on days 2 and 57
were used to determine the plasma concentrations of van-
detanib. The binding of vandetanib to plasma proteins
was also determined. Plasma concentrations of vande-
tanib and the concentrations in plasma ultra-filtrate were
determined using reverse-phase liquid chromatography
and detection by tandem mass spectrometry. Blood sam-
ples collected during screening and pre-dose on days 1, 2,
8, 15, 29 and 57, and at withdrawal were used to deter-
mine levels of VEGF, EGFR, sVEGFR-2, tunica interna
endothelial cell kinase (Tie2), basic fibroblast growth fac-
tor (bFGF), Angiopoietin-1 (Ang1) and Ang2. VEGF and
bFGF were measured in EDTA-plasma samples and the
remaining markers measured in serum as described previ-
ously [7].
Statistical analyses
The effect of vandetanib on MRI parameters was assessed
using repeated measures analysis of variance (ANOVA)
model fitted to loge transformed variables, with baseline
as a covariate, dose and visit as fixed effects, and subjects
as a random effect. Comparisons were performed to pro-
vide the least squares estimates and corresponding 95%
CIs at each visit. Results are reported as the mean percent-
age change and associated 95% CI from baseline by dose.
The proportion of patients with a >40% reduction post-
baseline for Ktrans and iAUC60 has been summarized for
each dose level; the >40% threshold was predefined and
has been used previously for detection of anti-vascular
activity by DCE-MRI [7]. One-sided P values were calcu-
lated for dose comparison of percentage decreases fromJournal of Angiogenesis Research 2009, 1:5 http://www.jangiogenesis.com/content/1/1/5
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baseline in Ktrans, iAUC60 and LCDCE-MRI. The effect of
vasoactive agents on T2*, and whether this produces an
increase or a decrease of T2*, depends on the balance
between any change of blood volume and blood flow
coupled with any change in oxygen utilization [25]. Since
this effect could not be predicted in the present study, a
two-sided  P  value was calculated for T2*. Population
pharmacokinetic and pharmacokinetic-pharmacody-
namic modeling was conducted using NONMEM soft-
ware [26,27].
Results
Patients
From 15 August 2006, 22 patients were enrolled in two
centers in Germany and received study treatment; 10
patients were randomized to the vandetanib 100 mg
group and 12 patients to the vandetanib 300 mg group
(Table 1). The analysis population consisted of all sub-
jects who had received at least one dose of vandetanib
(intent-to-treat [ITT]). Eighteen patients continued study
treatment until progression, three patients discontinued
(two due to an adverse event, one due to violation of
exclusion criteria) and one patient was ongoing on vande-
tanib 300 mg at data cut-off (22 June 2007). Median
exposure to vandetanib was 34 days (range 28-58) in the
100 mg group and 60 days (range 9-202) in the 300 mg
group. The demographic characteristics and previous anti-
cancer treatments were generally well balanced between
the two cohorts, although there were more female
patients in the vandetanib 300 mg group than in the 100
mg group.
MRI results
Primary variables
An assessment of the within-patient variability in iAUC60
and Ktrans revealed that these baseline DCE-MRI measure-
ments were reproducible, with low estimated intrapatient
coefficients of variation (11.3%, iAUC60; 24%, Ktrans).
While differences were identified between the two base-
line measurements for both parameters, Bland-Altman
plot analyses supported the definition of baseline as the
average of the two baseline measurements (Fig. 1a and
1b). The magnitude of change in either iAUC60 or Ktrans
was not significantly different between the vandetanib
100 mg and 300 mg cohorts (Table 2). The mean %
changes from baseline in iAUC60 and Ktrans showed small
reductions in both treatment groups (Table 2; Fig. 2a and
2b). The best change from baseline in iAUC60 and Ktrans for
each patient is shown in Fig. 3a and 3b, respectively. One
patient in each cohort showed at least once a >40% reduc-
tion from baseline in iAUC60. Four patients in each cohort
showed at least once a comparable decrease of >40% in
Ktrans. Consecutive decreases of >40% were not observed
in any patients for iAUC60 and in only two patients for
Ktrans. Fig. 4 illustrates composite MRI parametric images.
Exploratory variables
Mean T2* was measured as a function of tumor oxygena-
tion using intrinsic susceptibility MRI. Deoxyhemoglobin
creates a large magnetic disturbance next to blood vessels
inducing signal loss on MR images which can be quanti-
fied by T2* shortening. Therefore T2* can be used to
monitor changes in the concentration of deoxyhemo-
globin, whether this is caused by fractional desaturation
of oxygen from red blood cells or blood flow alterations.
In the absence of any change of blood volume, agents that
decrease blood flow and oxygenation may therefore
decrease T2*. Baseline T2* measurements were reproduc-
ible, with a low intrapatient coefficient of variation
(12.5%). Analysis of the mean change in T2* from base-
line revealed a dose effect; the increase in T2* in the 300
mg cohort was significantly different from the small
Table 1: Patient characteristics (ITT population)
Baseline characteristics Vandetanib 100 mg
(n = 10)
Vandetanib 300 mg
(n = 12)
Median age, years (range) 62.5 (38--77) 61 (41--73)
Male (%) 6 (60) 5 (42)
Female (%) 4 (40) 7 (58)
Race
Caucasian (%) 10 (100) 12 (100)
WHO performance status (%)
0
1
6 (60)
4 (40)
8 (67)
4 (33)
Previous chemotherapy regimens (%)
Any 10 (100) 12 (100)
1 1 (10) 4 (33)
2 3 (30) 2 (17)
3 or more 6 (60) 6 (50)
Prior cetuximab therapy (%) 7 (70) 7 (58)
Prior bevacizumab therapy (%) 5 (50) 4 (33)Journal of Angiogenesis Research 2009, 1:5 http://www.jangiogenesis.com/content/1/1/5
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decrease observed in the 100 mg cohort (two-sided P =
0.006; Table 2, Fig. 2c). Similar results were obtained for
median T2* (data not shown).
The length of the longest diameter of target lesion (LDDCE-
MRI) was recorded in the pre-contrast DCE-MRI scan. Anal-
ysis of the LDDCE-MRI data from days 2, 8, 29 and 57
showed mean increases from baseline in both cohorts.
These increases were less pronounced in the 300 mg
cohort, with evidence of a significant dose effect (one-
sided  P  = 0.029; Table 2). A similar trend was also
observed for the lesion area, although with a larger intra-
patient co-efficient of variation, which was expected due
to repositioning of the imaging slice between scans (data
not shown).
Pharmacokinetics
After two doses of vandetanib, both the area under the
curve to 24 h (AUC0-24) and the maximum concentration
(Cmax) increased in a dose proportional manner, with
gmean AUC0-24 of 1370 ng/mL·h (100 mg) and 4913 ng/
mL·h (300 mg), and gmean Cmax of 72.7 ng/mL (100 mg)
and 268.5 ng/mL (300 mg). The gmean accumulation at
steady state was 4.3-fold in the 300 mg group and 6.12-
fold for the one evaluable patient in the 100 mg dose
group. Determination of Cmin  throughout the study
period showed that steady-state exposure was achieved
from day 15 onwards (Fig. 5). The fraction of vandetanib
unbound on day 2 was approximately 0.065 for both
doses and, based on the 300 mg cohort, this was unaltered
at the higher levels observed at steady state. A population
pharmacokinetic-pharmacodynamic analysis showed lit-
Table 2: Mean % change from baseline in MRI parameters (full analysis set)
Mean % change from baseline (95% confidence interval) P value*
(300 mg vs. 100 mg)
Vandetanib 100 mg Vandetanib 300 mg
Primary variables
iAUC60 --3.4 (--13.6, 8.1) --4.6 (--13.4, 5.0) 0.429 (one-sided)
Ktrans --4.6 (--22.4, 17.4) --2.7 (--18.4, 16.2) 0.558 (one-sided)
Exploratory variables
T2* --2.2 (--7.1, 2.9) 7.3 (3.1, 11.7) 0.006 (two-sided)
LDDCE-MRI 16.1 (9.7, 22.9) 8.0 (2.9, 13.4) 0.029 (one-sided)
iAUC60 initial area under the DCE-MRI contrast agent concentration--time curve after 60 s
Ktrans volume transfer constant between blood plasma and extravascular extracellular space
T2* effective magnetic transverse relaxation time
LDDCE-MRI length of longest diameter of target lesion measured as part of the DCE-MRI acquisition protocol
*The effect of vandetanib on MRI parameters was assessed using repeated measures ANOVA, which was fitted to the log-transformed baseline as a 
covariate and dose as a factor. Point and interval estimates were exponentially back transformed to provide the estimates of the % differences. The 
preplanned statistical comparisons were between the dose levels and not within dose levels. Only the least squares mean (95% CI) changes are 
reported within dose. See 'Statistical analyses' section for full details
Bland-Altman plot comparing initial and second baseline val- ues for (a) iAUC60 and (b) Ktrans Figure 1
Bland-Altman plot comparing initial and second 
baseline values for (a) iAUC60 and (b) Ktrans. The differ-
ence between baseline values and mean baseline values is 
based on logarithmically transformed data.
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tle evidence of any correlation between the DCE-MRI var-
iables and either the plasma concentration, daily exposure
or total exposure to free or total vandetanib (data not
shown).
Soluble markers of angiogenesis/tumor activity
Higher plasma levels of VEGF were detected at both van-
detanib doses following multiple dosing, although large
variability was observed (data not shown). There was no
suggestion of a dose effect. No consistent time- or dose-
related changes from baseline were observed for the other
markers evaluated (sVEGFR-2, bFGF, EGFR, Tie-2, Ang1
and Ang2; data not shown).
Efficacy
There were no RECIST-defined objective responses as
assessed by contrast-enhanced CT. Among the 21 evalua-
ble patients, five patients in the 300 mg group had a best
response of stable disease ≥8 weeks and the remaining 16
patients experienced progressive disease. One patient in
the 300 mg group had no post-baseline measurements
and was therefore not evaluable. A waterfall plot of the
best percentage change from baseline in the size of target
lesions is presented in Fig. 6. Median PFS was 62 days
(95% CI, 57 to 177) in the 300 mg group and 34 days
(95% CI, 33 to 37) in the 100 mg group.
Safety and tolerability
Both vandetanib doses were generally well tolerated. The
most frequently reported adverse events, irrespective of
causality, were fatigue, diarrhea, dry mouth and nausea
(Table 3). More adverse events were reported in the 300
mg group compared with the 100 mg group, which is con-
sistent with the greater number of days on treatment for
the 300 mg group. The majority of adverse events were
CTCAE grade 1 or 2, including all cases of diarrhea. The
Estimated percentage change from baseline in (a) iAUC60, (b) Ktrans, and (c) T2* mean Figure 2
Estimated percentage change from baseline in (a) iAUC60, (b) Ktrans, and (c) T2* mean.
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most common adverse events considered by the investiga-
tor to be related to vandetanib were dry mouth, dyspho-
nia (both n = 5), diarrhea, fatigue, acne, dry skin (all n =
4) and hypertension (n = 3). Four of these adverse events
were CTCAE grade 3 (all n = 1): allergic dermatitis, fatigue,
photosensitivity reaction (all 300 mg) and hypertension
(100 mg). No grade 4 events were reported. Adverse
events that were considered by the investigator to be
related to study treatment were mostly manageable by
dose reductions or interruptions. Two patients in the 300
mg group experienced adverse events that led to discon-
tinuation of treatment: allergic dermatitis and photosen-
sitivity reaction (both grade 3) in one patient and QTc
prolongation (grade 2) in another. Nine deaths occurred
during this study before data cut-off and all were as a
result of disease progression. Clinical laboratory evalua-
tions did not show any clinically relevant changes in any
clinical chemistry, hematology and urinalysis parameter.
There was also no consistent trend in mean blood pres-
sure values, although increases in systolic and/or diastolic
blood pressure were observed during treatment, particu-
larly in patients with a history of hypertension or patients
who were borderline hypertensive at study entry. These
increases in blood pressure were considered by the inves-
tigator to be related to vandetanib.
Discussion
This randomized, open-label study used DCE-MRI to
investigate the effect of once-daily oral dosing with vande-
tanib (100 mg or 300 mg) on tumor perfusion and vascu-
lar permeability in 22 patients with advanced colorectal
cancer and liver metastases. The primary DCE-MRI varia-
bles of iAUC60 and Ktrans did not show any statistically sig-
nificant changes from baseline for either treatment group.
Therefore, the study did not support the hypothesis that
vandetanib has effects on tumor vasculature, as defined by
changes in gadolinium uptake measured by iAUC60 and
Ktrans. The safety and pharmacokinetic profiles of vande-
tanib were similar to those observed in previous phase I
studies [15,16]. Both vandetanib doses were generally
well tolerated with no new toxicities reported. A prelimi-
nary assessment of efficacy showed no RECIST objective
responses in either treatment group, with five patients in
the 300 mg group experiencing a best response of stable
disease.
There are several possible explanations for the absence of
detectable changes in gadolinium uptake and tumor
shrinkage with vandetanib in this setting. Although varia-
tions in institutional DCE-MRI protocols and different
patient populations do not permit direct comparison,
studies of other VEGFR-2 tyrosine kinase inhibitors have
demonstrated reductions in iAUC/Ktrans in patients with
advanced cancer [7-10]. Therefore, one explanation could
be that vandetanib is not sufficiently active versus VEGFR-
2 at the two doses investigated. However, this seems
unlikely given that vandetanib has previously demon-
strated single-agent antitumor activity at 100 mg and 300
mg in NSCLC [17] and in medullary thyroid cancer
[18,19]; the present study also showed some evidence of
antitumor effects (though not tumor shrinkage), with five
patients in the 300 mg cohort experiencing stable disease.
Inhibition of EGFR (NSCLC) and RET (medullary thyroid
cancer) tyrosine kinases is also likely to be contributing to
the activity of vandetanib in these tumor types; neverthe-
less, its relatively greater potency versus VEGFR-2 in vitro
[14] suggests that vandetanib should achieve at least com-
parable inhibition of VEGFR-2 versus EGFR/RET in vivo.
Moreover, in the present study, both vandetanib doses
achieved steady-state plasma drug levels that were several-
fold greater than the IC50 for inhibition of VEGF-depend-
ent proliferation of human umbilical vein endothelial
cells (29 ng/mL) [28]. An anti-VEGFR-2 effect of vande-
tanib at 100 mg and 300 mg is also supported by an
exploratory pharmacodynamic study in patients with
breast cancer, which showed inhibition of VEGFR-2 phos-
phorylation in skin biopsy tissue after 28 days of vande-
tanib treatment [29].
Best percentage change from baseline in (a) iAUC60 and (b)  Ktrans Figure 3
Best percentage change from baseline in (a) iAUC60 
and (b) Ktrans. The best percentage change is defined as the 
biggest decrease, or smallest increase if no decrease. The 
threshold of activity was considered to be 40% (dashed line).
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Example parameter maps calculated from MRI data Figure 4
Example parameter maps calculated from MRI data. Both patients received vandetanib 300 mg and had RECIST-
defined progressive disease on day 57 (patient 1983, Panel a) and day 62 (patient 2999, Panel b). Only the cutout of the lesion 
is shown. Definitions: Ktrans volume transfer constant between blood plasma and extravascular extracellular space Ve, extravas-
cular extracellular volume fraction; Unfit image pixels, which could not be fitted by DCE-MRI models (low uptake of contrast 
agent); iAUC60 initial area under the DCE-MRI contrast agent concentration--time curve after 60 s; R10 native longitudinal 
relaxation rate constant before contrast agent administration;T2* effective transverse relaxation time.
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A second explanation may be that vandetanib is not active
against the tumor vasculature in this particular disease set-
ting. Indeed, the antitumor effects of vandetanib in this
group of patients with colorectal cancer were modest com-
pared with its single-agent activity in NSCLC [17] or med-
ullary thyroid cancer [18,19]. Furthermore, the canonical
changes in plasma VEGF and VEGFR-2 that have been
observed with vandetanib in NSCLC [17] and with other
VEGFR tyrosine kinase inhibitors across different tumor
types [7,30] were not seen in the present study. In patients
with colorectal cancer, objective tumor responses and
effects on gadolinium uptake in tumor vasculature have
been observed in single-agent studies of cediranib [7] and
vatalanib [31]. Both of these VEGFR tyrosine kinase inhib-
itors, as well as bevacizumab, have activity versus VEGFR-
1 and VEGFR-2 signaling [32,33]. In contrast, vandetanib
is selective for VEGFR-2 versus VEGFR-1 [28]. It is known
that colorectal tumor cells express VEGFR-1 and that auto-
crine signaling may play a role in tumor cell survival/
migration [34]. Activity versus VEGFR-1 may therefore be
an important contribution to any effects of antiangiogenic
agents on both RECIST assessments and gadolinium
uptake in colorectal cancer. In this respect, it is interesting
that a recent pan-tumor study with CDP791, a high affin-
ity PEGylated di-Fab conjugate that specifically binds
VEGFR-2, showed limited efficacy and no effect on Ktrans
[35].
As discussed above, vandetanib has additional activity
versus EGFR and the adverse event profile of vandetanib
in this and previous studies [17,36,37] is consistent with
pharmacodynamic inhibition of both VEGFR (hyperten-
sion) and EGFR signaling (rash, diarrhea). Combining
inhibition of VEGF (bevacizumab) and EGFR (cetuxi-
mab) signaling on a background of chemotherapy has
been investigated in two recent colorectal cancer studies,
which produced different outcomes. The exploratory effi-
cacy results from the BOND-2 study in irinotecan-refrac-
tory, bevacizumab- and cetuximab-naïve patients
suggested that adding bevacizumab to cetuximab ± iri-
notecan may be more effective compared with historical
controls [38]. However, the first-line CAIRO-2 study
found that adding cetuximab to bevacizumab, capecitab-
ine and oxaliplatin resulted in a significantly shorter PFS
[39]. The CAIRO-2 authors speculated that these results
may be due to a negative interaction between cetuximab
and bevacizumab, and noted that the incidence of hyper-
tension, a relatively common side effect of treatment with
bevacizumab and other VEGF signaling inhibitors, was
significantly reduced in patients receiving cetuximab.
These data suggest, at least in some settings, that the vas-
cular effects associated with VEGF inhibition may be
diminished with concomitant EGFR inhibition. Other
than vandetanib, AEE788 is the only dual VEGFR and
EGFR tyrosine kinase inhibitor in clinical development
and it is worth noting that AEE788 also showed no effect
on gadolinium uptake in patients with advanced colorec-
tal cancer and liver metastases [40]. An additional factor
in the present study is that most patients had received pre-
vious treatment with bevacizumab and/or cetuximab,
which may have affected responsiveness to subsequent
VEGFR-2/EGFR tyrosine kinase inhibition. The mecha-
nism of tumor resistance to the monoclonal antibodies
bevacizumab and cetuximab is not well understood and
warrants further investigation.
It is also possible that vandetanib treatment may induce
hemodynamic changes, such as normalization/remode-
ling of the tumor vasculature as hypothesized by Jain [41],
that would not necessarily be detected by estimating
changes in Ktrans and iAUC60. More complex DCE-MRI
approaches such as the St Lawrence and Lee model [42],
Cmin plasma concentrations (ng/mL) for vandetanib 100 mg  and 300 mg Figure 5
Cmin plasma concentrations (ng/mL) for vandetanib 
100 mg and 300 mg. Data are shown as geometric mean 
(± SD).
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which is able to derive independent measurement of
blood flow, blood volume and permeability surface area,
may be more appropriate for detecting complex changes
in tumor vascularity and hemodynamics. Normalization
of the tumor vasculature might also be expected to
improve tumor oxygenation and blood flow. In this
regard, the results from the exploratory assessment of T2*
using intrinsic susceptibility MRI merit discussion.
Changes in T2* can be used to monitor changes in deox-
yhemoglobin and an increase in T2* could result from
improved tumor oxygenation and blood flow (i.e., nor-
malization) [25]. However, T2* is influenced by other fac-
tors and is therefore a difficult parameter to interpret on
its own [25,43]. In the absence of detectable effects on
tumor hemodynamics as measured by DCE-MRI, an
increase in T2* could be attributed to an increase in tumor
cell death [43,44]. As such, the significant increase in T2*
at vandetanib 300 mg compared with 100 mg in the
present study may reflect increased tumor necrosis at the
higher dose. Further correlative work is needed to under-
stand the biological basis of changes in T2* in the clinical
setting.
Population pharmacokinetic-pharmacodynamic analyses
showed no correlation between vandetanib exposure and
any of the pharmacodynamic parameters analyzed. Given
the long half-life of vandetanib, it may take up to 4 weeks
for vandetanib to reach steady state [14]; in the present
study, steady state was attained from day 15 at the earliest,
but was mostly from day 22 onwards. It is not fully under-
stood how tumor growth/adaptation during this pro-
longed period of drug accumulation may affect
pharmacodynamic variables.
Conclusion
In the present study, DCE-MRI assessments of iAUC60 and
Ktrans provided no evidence that vandetanib modulated
gadolinium uptake within the tumor vasculature of
patients with advanced colorectal cancer and liver metas-
tases. As discussed, these findings from a small open-label
study of only 24 patients should be interpreted with cau-
tion, particularly since vandetanib has previously demon-
strated evidence of antitumor activity in phase II studies in
advanced NSCLC and medullary thyroid cancer that is
consistent with inhibition of VEGFR activity. Vandetanib
is one of a number of VEGF signaling inhibitors in clinical
development and each has a different pharmacological
profile [45]. We raise the possibility that the different
selectivity profiles could result in agent-specific pharma-
codynamic effects on tumor vasculature that may not be
completely accounted for by changes in DCE-MRI varia-
bles such as iAUC60 and Ktrans. Vandetanib continues to be
investigated in a range of other tumor types, including
colorectal cancer and phase III programs in advanced
NSCLC and medullary thyroid cancer.
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Table 3: Adverse events reported in >3 patients overall
Adverse event* Vandetanib 100 mg
(n = 10)
n (%)
Vandetanib 300 mg
(n = 12)
n (%)
Total (n = 22)
n (%)
Fatigue 6 (60) 7 (58) 13 (59)
Rash† 2 (20) 10 (83) 11 (50)
Diarrhea 2 (20) 7 (58) 9 (41)
Dry mouth 2 (20) 4 (33) 6 (27)
Nausea 3 (30) 3 (25) 6 (27)
Anorexia 3 (30) 2 (17) 5 (23)
Dysphonia 1 (10) 4 (33) 5 (23)
Abdominal pain 1 (10) 3 (25) 4 (18)
Acne 0 4 (33) 4 (18)
Cough 1 (10) 3 (25) 4 (18)
Dizziness 3 (30) 1 (8) 4 (18)
Dry skin 1 (10) 3 (25) 4 (18)
Flatulence 1 (10) 3 (25) 4 (18)
Hypertension 1 (10) 3 (25) 4 (18)
Insomnia 3 (30) 1 (8) 4 (18)
Nasopharyngitis 2 (20) 2 (17) 4 (18)
Peripheral edema 4 (40) 0 4 (18)
Sinus tachycardia 1 (10) 3 (25) 4 (18)
Weight decreased 1 (10) 3 (25) 4 (18)
*MedDRA-preferred term except for rash
†MedDRA grouped term, which includes the following preferred terms: dry skin, erythema, photosensitivity reaction, rash papular, rash pustular, 
dermatitis allergic, exfoliative rash, and rash erythematousJournal of Angiogenesis Research 2009, 1:5 http://www.jangiogenesis.com/content/1/1/5
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